The combination of accelerating profitability, strong cash flow, affirmed growth guidance, and new dividend policy suggests Kamada is transitioning to a more mature, cash-generative biopharma profile. The stock may re-rate if 2026 execution matches guidance, especially given the low market cap (~$515M). Monitor M&A activity and plasma collection ramp-up as future catalysts.
KMDA drugs
KMDA drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 11 $8.30entry
- T+1 · 8mo ago +1.64%α +3.12% · $8.43
- T+5 · 8mo ago +0.47%α +2.66% · $8.34
- T+20 · 7mo ago +2.55%α +2.02% · $8.51
- T+60 · 6mo ago −10.95%α −22.47% · $7.39
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Kamada Ltd. reported strong 2025 full-year results with revenue of $180.5 million (up 12% YoY), adjusted EBITDA of $42.0 million (up 23% YoY), and net income of $20.2 million (up 40% YoY). The company affirmed its 2026 guidance of $200M–$205M in revenue and $50M–$53M in adjusted EBITDA, while declaring its first annual cash dividend of $0.25 per share ($14.4M total).
Key Financial Metrics
Key Facts
- 2025 revenue: $180.5M (+12% YoY), driven by VARIZIG®, KEDRAB®, KAMRAB®, and GLASSIA® sales
- 2025 adjusted EBITDA: $42.0M (+23% YoY); net income: $20.2M (+40% YoY)
- Affirmed 2026 guidance: $200M–$205M revenue (+13% mid-point growth), $50M–$53M adjusted EBITDA (+23% mid-point growth)
- Generated $25.5M in operating cash flow; ended year with $75.5M in cash
- Declared first annual dividend of $0.25 per share ($14.4M total), payable April 6, 2026
- Secured $10M–$14M Canadian Blood Services tender extension through Q1-2028
Financial Impact
Revenue and earnings growth accelerating, with 2026 guidance implying sustained double-digit growth. Dividend adds shareholder return dimension.
Risk Factors
- Fourth-quarter deceleration: Q4 revenue up 15% but net income and adjusted EBITDA declined YoY
- Operating cash flow dropped to $25.5M in 2025 from $47.6M in 2024 due to working capital build
- Discontinuation of Phase 3 Inhaled AAT trial removes a key pipeline catalyst
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3253639 |
Track record
25 reports on KMDA
7 of 10 bullish or bearish reports moved the stock their way by T+5. Best: +16.13% at T+20 after the Aug 12, 2026 report. 9 of 10 went positive at some point.
Filters
- Nov 9, 20267d ago 6-K Bullish 6/10 No price data
- Nov 9, 20267d ago Press Release Bullish 6/10 Entry $7.71 to $8.11 Now $8.11 +5.19% ▲ +5.19% +6.88% vs SPY
- Nov 2, 202614d ago 6-K Neutral 2/10 Entry $7.36 to $7.71 Now $8.11 +10.19% ▲ +4.76% +4.68% vs SPY
- Oct 6, 20265w ago 6-K Neutral 4/10 Entry $8.11 to $7.69 Now $8.11 −0.00% ▼ −5.18% −5.04% vs SPY
- Oct 6, 20265w ago Press Release Bullish 6/10 Entry $8.11 to $7.69 Now $8.11 −0.00% ▼ −5.18% −5.04% vs SPY
- Oct 5, 20266w ago 6-K Neutral 2/10 Entry $8.11 to $7.69 Now $8.11 −0.00% ▼ −5.18% −5.04% vs SPY
- Sep 17, 20268w ago 6-K Bullish 6/10 Entry $8.67 to $8.83 Now $8.11 −6.46% ▲ +1.85% +1.24% vs SPY
- Sep 16, 20268w ago EFFECT Neutral 3/10 Entry $8.19 to $8.77 Now $8.11 −0.98% ▲ +7.08% +4.52% vs SPY
- Sep 10, 20269w ago 6-K Neutral 2/10 Entry $7.99 to $8.67 Now $8.11 +1.50% ▲ +8.51% +9.01% vs SPY
- Sep 3, 202610w ago Press Release Neutral 2/10 Entry $8.54 to $8.31 Now $8.11 −5.04% ▼ −2.69% −1.48% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers